Enhanced glutamatergic transmission reduces the anticonvulsant potential of lamotrigine but not of felbamate against tonic-clonic seizures

Pharmacological Reports

Volumn 59, Issue 4, 2007, Pages 462-466

  Tomczyk, Tomasz ^a   Haberek, Grzegorz ^a   Zuchora, Beata ^a   Jarosławska Zych, Agata ^b   Kowalczyk, Mieczysław S ^c   Wielosz, Marian ^a   Urbańska, Ewa M ^a,d  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b Cardinal Rev Wyszynski Voivodship Specialist Hospital   (Poland)

^c Centrum Onkologii Ziemi Lubelskiej   (Poland)

^d INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Epilepsy; Felbamate; Glutamate receptors; Lamotrigine; Pharmacoresistance

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; FELBAMATE; KAINIC ACID; LAMOTRIGINE; N METHYL DEXTRO ASPARTIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; ELECTRIC SHOCK; GRAND MAL SEIZURE; MALE; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIMARY PREVENTION; STATISTICAL SIGNIFICANCE; TONIC CLONIC SEIZURE;

EID: 35048900124     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Bradford HF: Glutamate, GABA and epilepsy. Prog Neurobiol, 1995, 47, 477-511.
2. Borowicz KK, Kleinrok Z, Czuczwar SJ: Glutamate receptor antagonists differentially affect the protective activity of conventional antiepileptics against amygdala-kindled seizures in rats. Eur Neuropsychopharmacol, 2001, 11, 61-68.
3. Czapiński P, Blasnczyk B, Czuczwar SJ: Mechanisms of action of antiepileptic drugs. Curr Top Med Chem, 2005, 5, 3-14.
4. Czuczwar SJ, Patsalos PN: The new generation of GABA enhancers. Potential in the treatment of epilepsy. CNS Drugs, 2001, 15, 339-350.
5. Czuczwar SJ, Turski WA, Kleinrok Z: Interaction of excitatory amino acid antagonists with conventional antiepileptic drugs. Metab Brain Dis, 1906, 1, 63-72.
6. Czuczwar SJ, Turski WA, Kleinrok Z: Excitatory amino acid-induced seizure activity and seizure-related brain damage - a possible therapeutic potential of glutamate antagonists. Pol J Pharmacol, 1998, 50, 85-87.
7. De Sarro G, Ongini E, Bertorelli R, Aguglia U, De Sarro A: Excitatory amino acid neurotransmission through both NMDA and non-NMDA receptors is involved in the anticonvulsant activity of felbamate in DBA/2 mice. Eur J Pharmacol, 1994, 262, 11-19.
8. Grigorenko E, Glazier S, Bell W, Tytell M, Nosel E, Pons T, Deadwyler SA: Changes in glutamate receptor subunit composition in hippocampus and cortex in patients with refractory epilepsy. J Neurol Sci, 1997, 153, 35-45.
9. Harty TB, Rogawski MA: Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res, 2000, 39, 47-55.
10. Leach MJ, Baxter MG, Critchley MA: Neurochemical and behavioral aspects of lamotrigine. Epilepsia, 1991, 32, S4-S8.
11. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
12. Löscher W: New vision in the pharmacology of anticon-vulsion. Eur J Pharmacol, 1998, 342, 1-13.
13. Meldrum BS: The role of glutamate in epilepsy and other CNS disorders. Neurology, 1994, 44, S14-S23.
14. Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML: Felbamate: consensus of current clinical experience. Epilepsy Res, 2006, 71, 89-101.
15. Philips I, Martin KF, Thompson KS, Heal DJ: Weak blockade of AMPA receptor-mediated depolarisations in the rat cortical wedge by phenytoin but not lamotrigine or carbamazepine. Eur J Pharmacol, 1997, 337, 189-195.
16. Proper EA, Hoogland G, Kappen SM, Jansen GH, Rensen MG, Schrama LH, van Veelen CW et al.: Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain, 2002, 125, 32-43.
17. Remy S, Beck H: Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain, 2006, 129, 18-35.
18. Turski WA, Dziki M, Urbańska E, Calderazzo-Filho LS, Cavalheiro EA: Seizures induced by aminooxyacetic acid in mice: pharmacological characteristics. Synapse, 1991, 7, 173-180.
19. Turski WA, Urbańska EM, Dziki M, Parada-Turska J, Ikonomidou C: Excitatory amino acid antagonists protects mice against seizures induced by bicuculline. Brain Res, 1990, 514, 131-134.
20. Urbańska EM, Blaszczak P, Saran T, Kleinrok Z, Turski WA: AMPA/ kainate-related mechanisms contribute to convulsant and proconvulsant effects of 3-nitropropionic acid. Eur J Pharmacol, 1999, 370, 251-256.
21. Urbańska EM, Czuczwar SJ, Kleinrok Z, Turski WA: Excitatory amino acids in epilepsy. Rest Neurol Neurosci, 1998, 13, 25-39.
22. Urbańska E, Dziki M, Kleinrok Z, Czuczwar SJ, Turski WA: Influence of MK-801 on the anticonvulsant activity of antiepileptics. Eur J Pharmacol, 1991, 200, 277-282.
23. Urbańska EM, Tomczyk T, Haberek G, Pilip S, Matyska J, Turski WA, Kleinrok Z, Czuczwar SJ: NMDA- but not kainate-mediated events reduce efficacy of some antiepileptic drugs against generalized tonic-clonic seizures in mice. Epilepsia, 1999, 40, 1507-1511.
24. Wang SJ, Huang CC,Hsu KS, Tsai JJ, Geau PW: Pre-synaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons. Synapse, 1996, 24, 248-255.
25. Wojtal K, Borowicz KY, Blaszczyk B, Czuczwar SJ: Interactions of excitatory amino acid receptor antagonists with antiepileptic drugs in three basic models of experimental epilepsy. Pharmacol Rep, 2006, 58, 587-598.
26. Zhang ZJ, Russell S, Obeng K, Postma T, Obrocea G, Weiss SR, Post RM: Coadministration of gabapentin or MK-801 with lamotrigine slows tolerance to its anticonvulsant effects on kindled seizures. Pharmacol Biochem Behav, 2003, 74, 565-571.